New CAR-T therapy aims to tackle Hard-to-Treat lymphoma
NCT ID NCT07093073
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing a new treatment called U01 (ssCART-19) for people with B-cell lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will enroll 30 participants to check safety and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
U01 (ssCART-19) CAR-T cells
What this could lead to
If successful, this could offer a new treatment option for patients with B-cell lymphoma that has not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 people, so it may not work for everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••